Cargando…
MAP2 is differentially phosphorylated in schizophrenia, altering its function
Schizophrenia (Sz) is a highly polygenic disorder, with common, rare, and structural variants each contributing only a small fraction of overall disease risk. Thus, there is a need to identify downstream points of convergence that can be targeted with therapeutics. Reduction of microtubule-associate...
Autores principales: | Grubisha, M. J., Sun, X., MacDonald, M. L., Garver, M., Sun, Z., Paris, K. A., Patel, D. S., DeGiosio, R. A., Lewis, D. A., Yates, N. A., Camacho, C., Homanics, G. E., Ding, Y., Sweet, R. A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325721/ https://www.ncbi.nlm.nih.gov/pubmed/33526823 http://dx.doi.org/10.1038/s41380-021-01034-z |
Ejemplares similares
-
More than a marker: potential pathogenic functions of MAP2
por: DeGiosio, Rebecca A., et al.
Publicado: (2022) -
MAP2 immunoreactivity deficit is conserved across the cerebral cortex within individuals with schizophrenia
por: DeGiosio, Rebecca, et al.
Publicado: (2019) -
Investigating Post-translational Modifications in Neuropsychiatric Disease: The Next Frontier in Human Post-mortem Brain Research
por: Grubisha, Melanie J., et al.
Publicado: (2021) -
Mapping Synaptic Pathology within Cerebral Cortical Circuits in Subjects with Schizophrenia
por: Sweet, Robert A., et al.
Publicado: (2010) -
Fingolimod mitigates synaptic deficits and psychosis‐like behavior in APP/PSEN1 mice
por: Krivinko, Josh M., et al.
Publicado: (2022)